VMAT2


Also found in: Wikipedia.
AcronymDefinition
VMAT2Vesicular Monoamine Transporter Type 2
References in periodicals archive ?
Hamer makes clear that, at most, VMAT2 is "a" God gene--not "the" God gene of his book's title.
Therefore, the Pitt researchers posited that increasing VMAT2 protein was the mechanism of action that boosted cognitive performance.
He relates in clear and approachable language the scientific story of his search and eventual discovery of VMAT2 in The God Gene.
Do popes and priests, preachers and prophets, monks and mendicants possess the VMAT2 gene?
Might we be able to be tested for VMAT2 much the same way we are tested for blood types and cholesterol levels?
This possibility can be explored in future studies because other dopamine terminal markers such as VMAT2 can be imaged and are less likely to be influenced by elevated levels of Mn in the striatum.
Although several of the dopamine neuron markers that were analyzed postmortem, such as dopamine and DOPAC (3,4-dihydroxyphenylacetic acid) in the putamen, DAT and VMAT2 in the caudate and putamen and D2R in the putamen were significantly lower in Mn-exposed animals than in naive controls; they were not different from all controls when the imaged control group was included.
The first set of clinical studies has demonstrated the ability of AV-133 PET imaging to visualize decreases in the VMAT2 signal in the brain associated with Parkinson's disease (PD) and Dementia with Lewy bodies (DLB).
During the first half of 2015 we have been focused on two primary tasks, executing on our Phase III Kinect clinical trials and beginning the commercial build for our VMAT2 inhibitor NBI-98854," said Kevin Gorman, Ph.
Avid's presentations at the upcoming SNM meeting will cover new research and development results on these F-18 radiopharmaceuticals: 18F-AV-45 for imaging amyloid plaque, a key pathological component of Alzheimer's disease, 18F-AV-133 for imaging VMAT2, a marker of dopaminergic synapse density which is affected in diseases such as Parkinson's disease and Dementia with Lewy bodies, as well as being a potential biomarker for beta cells, the key insulin-secreting cells of the pancreas which are effected in diabetes.
Chris Rowe from Austin Health in Melbourne Australia, will present: "In vivo quantification of striatal VMAT2 with [F-18] AV-133"